 This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg Sd dosed twice weekly in four-week cycles, in patients with penta-refractory MM Parts 1 and 2 or quad refractory MM Part 1 only. 